(NASDAQ: MREO) Mereo Biopharma Group's forecast annual revenue growth rate of 37.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 1,251.4%, and while it is forecast to beat the US market's average forecast revenue growth rate of 29.08%.
Mereo Biopharma Group's revenue in 2023 is $8,910,000.On average, 1 Wall Street analysts forecast MREO's revenue for 2023 to be $7,866,394,631, with the lowest MREO revenue forecast at $7,866,394,631, and the highest MREO revenue forecast at $7,866,394,631.
In 2024, MREO is forecast to generate $57,412,459,912 in revenue, with the lowest revenue forecast at $57,412,459,912 and the highest revenue forecast at $57,412,459,912.